Brii Biosciences Limited
腾盛博药生物科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2137)

INSIDE INFORMATION

THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES NOVEL NEUTRALIZING ANTIBODY COMBINATION THERAPY FOR THE TREATMENT OF COVID-19 IN CHINA

This announcement is made by Brii Biosciences Limited (the "**Company**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the inside information provision (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of the directors (the "**Board**") of the Company is pleased to announce that the National Medical Products Administration ("**NMPA**") of China has granted approval of the Company's monoclonal neutralizing antibody therapy, the amubarvimab/romlusevimab combination (previously BRII-196/BRII-198 combination), for the treatment in adults and pediatric patients (age 12-17 years and weighing at least 40 kg) with mild and normal type of COVID-19 at high risk for progression to severe disease, including hospitalization or death. The indication of pediatric patients (age 12-17 years and weighing at least 40 kg) is under a conditional approval.

The NMPA approval is based on positive final and interim results from the National Institute of Health of the United States of America ("**NIH**")-sponsored Phase 3 clinical trial with 847 enrolled patients, ACTIV-2, developed by NIH as part of the Accelerating COVID-19 Therapeutic Interventions Vaccines ("**ACTIV**") program clinical trial, in which the amubarvimab/romlusevimab combination demonstrated a statistically significant 80% (78% in interim results) reduction of hospitalization and death with fewer deaths through 28 days in the treatment arm (0) relative to placebo (9), and improved safety outcome over placebo in non-hospitalized COVID-19 patients at high risk of clinical progression to severe disease. Similar efficacy rates were observed in participants initiating therapy early (0-5 days) and late (6-10 days), following symptom onset, providing critically needed clinical evidence in COVID-19 patients who were late for treatment.

The approval marks the first locally-discovered and approved SARS-CoV-2 target-specific treatment in China through a randomized, double-blind, and placebo-controlled trial and represents the partnership with the best-in-class scientists and clinical investigators in China and around global on shared mission, including Tsinghua University and the 3rd People's Hospital of Shenzhen, who discovered these neutralizing antibody candidates; the NIH and the AIDS Clinical Trial Group, who sponsored and led the ACTIV-2 trial.

In addition, the Company is pursuing additional efforts and regulatory filings for the amubarvimab/romlusevimab combination in established and emerging markets with an initial focus on securing access in countries where clinical trials were conducted and where significant gaps in access to highly effective treatments have been identified. In China, the Company is planning further studies to evaluate the use of the amubarvimab/romlusevimab combination among immunocompromised population as an additional measurement of prophylaxis.

Cautionary Statement: There is no assurance that amubarvimab, and romlusevimab, will ultimately be successfully developed or marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, December 9, 2021

As at the date of this announcement, the Board comprises Dr. Zhi Hong and Mr. Yongqing Luo as executive directors; Mr. Robert Taylor Nelsen and Dr. Axel Bouchon as non-executive directors; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui and Mr. Gregg Huber Alton as independent non-executive directors.